ProQR Therapeutics (PRQR) Financial Statements & Analysis

ProQR Therapeutics (PRQR) Income Statement

ProQR Therapeutics reported revenue of EUR 16.35M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 13.5% from EUR 18.91M a year earlier. ProQR Therapeutics posted a net loss of EUR 42.18M, compared with a net loss of EUR 27.76M a year earlier. Gross margin was 100.0% and operating margin -265.8%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was EUR 8.90M, up 133.3% from the same quarter a year earlier.

ProQR Therapeutics Income Statement Analysis

Values in millions EUR

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

ProQR Therapeutics N.V. income statement - Annual data in millions EUR
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	16.35	18.91	6.51	3.59	2.38	1.03	1.93	4.94	-1.53
Cost of Revenue	2.60	0.00	0.00	0.00	0.00	0.00	116.82	0.98	1.00
Gross Profit	16.35	18.91	6.51	3.59	2.38	1.03	-114.89	3.96	-2.53
Operating Expenses
Research & Development	44.73	36.36	25.15	50.87	42.22	38.14	46.49	29.51	31.15
Selling, General & Administrative	15.06	13.66	16.24	18.65	17.37	13.69	12.89	12.54	10.84
Operating Expenses	59.79	49.38	41.30	68.75	59.59	43.40	59.38	42.05	41.99
Operating Income	-43.45	-30.47	-34.79	-65.16	-57.21	-42.37	-57.45	-36.29	-40.50
Other Income/Expense
Interest Income	2.33	3.25	2.59	0.11	1.52	0.31	0.40	-0.79	-3.18
Interest Expense	0.87	1.08	1.20	5.13	-3.41	2.04	1.08	0.81	0.60
Other Income/Expense	1.28	0.34	5.59	1.05	-3.47	-4.12	117.65	-0.79	0.85
Income
Income Before Tax	-42.17	-27.96	-27.81	-64.11	-60.68	-46.49	-56.61	-37.09	-43.67
Income Tax Expense	0.02	-0.20	-0.08	0.10	0.12	0.12	0.13	0.00	0.00
Net Income	-42.18	-27.76	-28.12	-64.42	-60.74	-46.57	-56.75	-36.89	-43.64
Net Income - Continuous Operations	-40.52	-27.76	-27.74	-64.42	-60.80	-46.57	-56.75	-36.89	-43.64
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-42.54	-24.12	-24.10	-56.46	-56.55	-48.44	-174.27	-35.29	0.00
EBIT	-43.45	-26.88	-26.61	-58.98	-57.21	-50.79	-	-	-
Depreciation & Amortization	2.60	2.76	2.51	2.52	0.66	2.36	2.05	0.98	1.00
Earnings Per Share
Basic EPS	-	-	-	-1.00	-1.00	-1.00	-1.00	-1.00	-2.00
Diluted EPS	-	-	-	-1.00	-1.00	-1.00	-1.00	-1.00	-2.00
Basic Shares Outstanding	105.33	86.09	81.01	71.64	64.18	50.06	41.04	34.05	25.37
Diluted Shares Outstanding	105.33	86.09	81.01	71.64	64.18	50.06	41.04	34.05	25.37

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ProQR Therapeutics Financial Statements

What was ProQR Therapeutics's revenue in fiscal 2025?

ProQR Therapeutics reported revenue of EUR 16.35M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 13.5% from EUR 18.91M a year earlier.

Is ProQR Therapeutics profitable?

No. ProQR Therapeutics reported a net loss of EUR 42.18M in fiscal 2025. In fiscal 2024 it lost EUR 27.76M.

What is ProQR Therapeutics's operating margin?

ProQR Therapeutics's operating income was −EUR 43.45M on revenue of EUR 16.35M in fiscal 2025, an operating margin of -265.8%, compared with -161.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition